Symbiotec Pharmalab IPO listing: Symbiotec Pharmalab share price listed at a discount on the BSE on Tuesday, 1 September, amid weak stock market sentiment. Symbiotec Pharmalab shares were listed at ₹978.20 on the BSE, down 1% from the issue price of ₹988. On the NSE, the stock debuted flat at ₹988.
Soon after the listing, the stock hit highs and lows of ₹1,120 and ₹933.80, respectively, on the BSE. On the NSE, the stock rose to ₹1,124.50 and declined to ₹934.20.
The stock’s listing failed to meet expectations, as the grey market premium (GMP) for Symbiotec Pharmalab on Tuesday morning was ₹185, suggesting the stock could list at ₹1,173, a premium of nearly 19% over the IPO price.
Meanwhile, stock market benchmarks, the Sensex and the Nifty 50, declined by up to 0.30% in morning deals.
is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and speciality products. It serves domestic and international markets across regulated and emerging regions.
Its revenue from operations for FY24 stood at ₹716.25 crore, increasing to ₹751.55 crore in FY25, and to ₹869.15 crore in FY26.
Profit attributable to owners of the parent company was ₹100.18 crore in FY24, ₹96.78 crore in FY25 and ₹109.88 crore in FY26.
Should investors buy more, book profits, or hold?
Most experts are positive about the stock over the long term, largely due to the company’s leadership position in corticosteroid and steroidal hormone APIs.
Saurabh Jain, the head of fundamental research at SMC Global Securities, underscored that Symbiotec’s outlook appears positive for the long term due to its leadership in corticosteroid and steroidal-hormone APIs, backward integration, regulatory credentials, and established global customer base.
“Expansion into biologics, CDMO services, alternative proteins and complex injectables provides additional growth avenues beyond its core API business,” said Jain.
“The commissioning and expansion of fermentation capacity could support future volumes and diversification. However, customer concentration, dependence on selected suppliers, regulatory requirements and execution of new capacities remain key factors to monitor,” said Jain.
Sunny Agrawal, the head of fundamental research at SBI Securities, suggests holding the stock for the long term.
“We continue to maintain a positive stance on the business and recommend investors continue to hold the stock for the long term. The company is a global leader in corticosteroid and steroidal-hormone APIs in volume terms,” said Agrawal.
Shivani Nyati, Head of Wealth at Swastika Investmart, also believes the stock is suitable for long-term investors.
“For someone allotted shares, this isn’t a stock to chase for quick gains; it suits investors willing to hold long-term for the API leadership story. Keep a stop loss around ₹930 (about 5% below listing) – if it breaks that, exit and don’t average down,” said Nyati.
Nyati said that Symbiotec Pharmalab is a global leader in corticosteroid and steroidal-hormone APIs. This is a specialised business with high entry barriers due to complex manufacturing and strict regulatory approvals.
However, she underscored that at nearly 57 times P/E, it’s priced richer than its FY26 return ratios justify (ROE nearly 11.2%, ROCE nearly 11.6%), and the ₹1,757 crore issue was mostly an OFS by promoters and PE investors – only ₹150 crore actually goes to the company for growth.
“The flat listing suggests the market isn’t excited about the valuation right now,” said Nyati.
Symbiotec Pharmalab IPO details
Symbiotec Pharmalab IPO was a , combining a fresh issue of 15.21 lakh shares to raise ₹150 crore and an offer for sale (OFS) of 1.63 crore shares, aggregating to ₹1,607 crore.
The company aimed to raise ₹150 crore through the fresh issue of shares, which it will use for loan repayment and general corporate purposes.
The IPO opened for public subscription on Monday, 24 August, and concluded on Thursday, 27 August, with an overall subscription of 75 times. Share allotment was finalised on Friday, 28 August.
Read all market-related news
Read more stories by
Disclaimer: This article is for educational purposes only and does not constitute investment advice. The views and recommendations expressed are those of individual analysts or broking firms, not Mint. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.